Institutional members access full text with Ovid®

Share this article on:

Combination Therapy in Pediatric Inflammatory Bowel Disease: Yes, No, Maybe

Hyams, Jeffrey S. MD*; Kugathasan, Subra MD; Dubinsky, Marla C. MD

doi: 10.1097/MIB.0000000000001206
Commentary

Article first published online 22 August 2017.

*Division of Gastroenterology, Hepatology, and Nutrition, Connecticut Children's Medical Center, Hartford, Connecticut;

Division of Gastroenterology, Hepatology, and Nutrition, Mount Sinai Hospital, New York, New York; and

Division of Gastroenterology, Hepatology, and Nutrition, Emory University, Atlanta, Georgia.

Jeffrey S. Hyams, MD, serves on the Advisory Board for Janssen, and as a consultant for Abbvie, Celgene, Takeda, Lilly, and UCB. Subra Kugathasan, MD, serves as a consultant for Janssen, Abbvie, and UCB. Marla C. Dubinsky, MD, serves as a consultant for Janssen, Abbvie, Pfizer, Celgene, Takeda, UCB, Salix, and Prometheus.

Received June 03, 2017

Accepted June 05, 2017

© Crohn's & Colitis Foundation
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website